A Study to Assess Stroke Risk Among Users of Typical Versus Atypical Antipsychotics Stratified by Broad Age Group

CompletedOBSERVATIONAL
Enrollment

1,234,412

Participants

Timeline

Start Date

May 6, 2019

Primary Completion Date

May 31, 2019

Study Completion Date

May 31, 2019

Conditions
Stroke
Interventions
DRUG

Haloperidol

Stroke rates among participants from 01 January, 2002 through 31 December 2017 will be estimated among new users of haloperidol. No drug will be administered as part of this study.

DRUG

Typical Antipsychotics

Stroke rates among participants from 01 January, 2002 through 31 December 2017 will be estimated among new users of typical antipsychotics which includes Haloperidol, Loxapine, Thioridazine, Molindone, Thiothixene, Fluphenazine, Trifluoperazine, Perphenazine, Chlorpromazine. No drug will be administered as part of this study.

DRUG

Atypical Antipsychotics

Stroke rates among participants from 01 January, 2002 through 31 December 2017 will be estimated among new users of atypical antipsychotics which includes Aripriprazole, Asenapine, Brexpiprazole, Cariprazine, Clozapine, Iloperidone, Lurasidone, Paliperidone, Ziprasidone, Risperidone, Quetiapine, Olanzapine. No drug will be administered as part of this study.

Trial Locations (1)

08560

Janssen Investigative Site, Titusville

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY

NCT04002700 - A Study to Assess Stroke Risk Among Users of Typical Versus Atypical Antipsychotics Stratified by Broad Age Group | Biotech Hunter | Biotech Hunter